share_log

Acrivon Therapeutics Analyst Ratings

Acrivon Therapeutics Analyst Ratings

Acrivon 治療師評級
Benzinga ·  2023/11/11 04:00
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/10/2023 455.56% BMO Capital $25 → $24 Maintains Outperform
10/05/2023 455.56% Maxim Group → $24 Initiates Coverage On → Buy
09/06/2023 362.96% HC Wainwright & Co. → $20 Reiterates Buy → Buy
08/18/2023 501.85% JonesTrading → $26 Initiates Coverage On → Buy
08/11/2023 362.96% HC Wainwright & Co. $21 → $20 Reiterates Buy → Buy
06/02/2023 478.7% Oppenheimer → $25 Initiates Coverage On → Outperform
05/08/2023 478.7% BMO Capital → $25 Initiates Coverage On → Outperform
05/02/2023 455.56% HC Wainwright & Co. → $24 Reiterates → Buy
04/20/2023 455.56% HC Wainwright & Co. → $24 Initiates Coverage On → Buy
12/12/2022 — Cowen & Co. Initiates Coverage On → Outperform
12/12/2022 293.52% Jefferies → $17 Initiates Coverage On → Buy
12/12/2022 478.7% Piper Sandler → $25 Initiates Coverage On → Overweight
日期 上行/下行 分析公司 目標價格變動 評級變動 之前/當前的評級
11/10/2023 455.56% BMO Capital 25 美元 → 24 美元 維護 跑贏大盤
10/05/2023 455.56% Maxim 集團 → 24 美元 啓動覆蓋範圍開啓 → 購買
09/06/2023 362.96% HC Wainwright & Co. → 20 美元 重申 購買 → 購買
08/18/2023 501.85% JonesTrading → 26 美元 啓動覆蓋範圍開啓 → 購買
08/11/2023 362.96% HC Wainwright & Co. 21 美元 → 20 美元 重申 購買 → 購買
06/02/2023 478.7% 奧本海默 → 25 美元 啓動覆蓋範圍開啓 → 跑贏大盤
05/08/2023 478.7% BMO Capital → 25 美元 啓動覆蓋範圍開啓 → 跑贏大盤
05/02/2023 455.56% HC Wainwright & Co. → 24 美元 重申 → 購買
04/20/2023 455.56% HC Wainwright & Co. → 24 美元 啓動覆蓋範圍開啓 → 購買
2022 年 12 月 12 日 — Cowen & Co. 啓動覆蓋範圍開啓 → 跑贏大盤
2022 年 12 月 12 日 293.52% 傑富瑞集團 → 17 美元 啓動覆蓋範圍開啓 → 購買
2022 年 12 月 12 日 478.7% 派珀·桑德勒 → 25 美元 啓動覆蓋範圍開啓 → 超重

What is the target price for Acrivon Therapeutics (ACRV)?

Acrivon Therapeutics（ACRV）的目標價格是多少？

The latest price target for Acrivon Therapeutics (NASDAQ: ACRV) was reported by BMO Capital on November 10, 2023. The analyst firm set a price target for $24.00 expecting ACRV to rise to within 12 months (a possible 455.56% upside). 12 analyst firms have reported ratings in the last year.

BMO Capital於2023年11月10日公佈了Acrivon Therapeutics（納斯達克股票代碼：ACRV）的最新目標股價。該分析公司將目標股價定爲24.00美元，預計ACRV將在12個月內升至12個月內（可能上漲455.56％）。去年有12家分析公司公佈了評級。

What is the most recent analyst rating for Acrivon Therapeutics (ACRV)?

分析師對Acrivon Therapeutics（ACRV）的最新評級是多少？

The latest analyst rating for Acrivon Therapeutics (NASDAQ: ACRV) was provided by BMO Capital, and Acrivon Therapeutics maintained their outperform rating.

BMO Capital對Acrivon Therapeutics（納斯達克股票代碼：ACRV）的最新分析師評級由BMO Capital提供，Acrivon Therapeutics維持跑贏大盤的評級。

When is the next analyst rating going to be posted or updated for Acrivon Therapeutics (ACRV)?

Acrivon Therapeutics（ACRV）的下一次分析師評級何時公佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acrivon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acrivon Therapeutics was filed on November 10, 2023 so you should expect the next rating to be made available sometime around November 10, 2024.

分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Acrivon Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Acrivon Therapeutics的最新評級是在2023年11月10日公佈的，因此您應該預計下一個評級將在2024年11月10日左右公佈。

Is the Analyst Rating Acrivon Therapeutics (ACRV) correct?

分析師對Acrivon Therapeutics（ACRV）的評級是否正確？

While ratings are subjective and will change, the latest Acrivon Therapeutics (ACRV) rating was a maintained with a price target of $25.00 to $24.00. The current price Acrivon Therapeutics (ACRV) is trading at is $4.32, which is out of the analyst's predicted range.

儘管評級是主觀的，並且會發生變化，但最新的Acrivon Therapeutics（ACRV）評級保持不變，目標股價爲25美元至24.00美元。Acrivon Therapeutics（ACRV）目前的交易價格爲4.32美元，超出了分析師的預期區間。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論